Johnl Higgins News Today

OmniAb (NASDAQ:OABI – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $11.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 101.47% from the company’s current […]

OmniAb, Inc. (NASDAQ:OABI – Free Report) has received an average rating of “Buy” from the nine analysts that are covering the company, Marketbeat.com reports. Nine research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued a report on the stock in the last year is […]

OmniAb, Inc. (NASDAQ:OABI – Get Rating) has been given an average recommendation of “Buy” by the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have updated their coverage on the stock in the […]

OmniAb, Inc. (NASDAQ:OABI – Get Rating) Director John L. Higgins sold 50,000 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $3.89, for a total transaction of $194,500.00. Following the completion of the transaction, the director now directly owns 2,462,686 shares of the […]

Ligand Pharmaceuticals (NASDAQ:LGND – Get Rating) had its price objective upped by Roth Capital from $85.00 to $90.00 in a research note issued to investors on Friday, The Fly reports. Roth Capital currently has a buy rating on the biotechnology company’s stock. A number of other research analysts have also weighed in on LGND. StockNews.com […]

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Affiance Financial LLC lowered its holdings in Bio-Techne Co. (NASDAQ:TECH – Get Rating) by 7.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,258 shares of the biotechnology company’s stock after selling 473 shares during the quarter. Bio-Techne accounts for about […]

Bio-Techne (NASDAQ:TECH – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Friday, Zacks.com reports. The firm currently has a $408.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 14.79% from […]